Stockreport

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Celcuity Inc.  (CELC) 
Last celcuity inc. earnings: 3/12 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: celcuity.com/home/investors
PDF For patients whose time to progression on immediate prior therapy was 18 months, median progression-free survival (“PFS”) was 12.4 months with gedatolisib + palbociclib [Read more]